Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation.

Blood
Cheng C ZhangHarvey F Lodish

Abstract

Hematopoietic stem cells (HSCs) are the basis of bone marrow transplantation and are attractive target cells for hematopoietic gene therapy, but these important clinical applications have been severely hampered by difficulties in ex vivo expansion of HSCs. In particular, the use of cord blood for adult transplantation is greatly limited by the number of HSCs. Previously we identified angiopoietin-like proteins and IGF-binding protein 2 (IGFBP2) as new hormones that, together with other factors, can expand mouse bone marrow HSCs in culture. Here, we measure the activity of multipotent human severe combined immunodeficient (SCID)-repopulating cells (SRCs) by transplantation into the nonobese diabetic SCID (NOD/SCID) mice; secondary transplantation was performed to evaluate the self-renewal potential of SRCs. A serum-free medium containing SCF, TPO, and FGF-1 or Flt3-L cannot significantly support expansion of the SRCs present in human cord blood CD133+ cells. Addition of either angiopoietin-like 5 or IGF-binding protein 2 to the cultures led to a sizable expansion of HSC numbers, as assayed by NOD/SCID transplantation. A serum-free culture containing SCF, TPO, FGF-1, angiopoietin-like 5, and IGFBP2 supports an approximately 20-fo...Continue Reading

References

Jan 1, 1997·Hormone Research·M B Ranke, M Elmlinger
Jan 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Christopher J HoganGordon Keller
Mar 27, 2002·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·S HolminA C Sandberg Nordqvist
Mar 8, 2003·Journal of Human Genetics·Li ZengYumin Mao
Jul 4, 2003·The Journal of Clinical Investigation·Guénahel H DanetM Celeste Simon
Jun 3, 2004·Journal of Molecular Endocrinology·B S SchüttM W Elmlinger
Aug 6, 2004·International Journal of Hematology·Yuichi OikeToshio Suda
Sep 21, 2004·Oncogene·Guy SauvageauR Keith Humphries
Aug 6, 2005·Cytotherapy·S RobinsonE Shpall
Jan 18, 2006·Annual Review of Medicine·Claudio G Brunstein, John E Wagner
Jan 24, 2006·Nature Medicine·Cheng Cheng ZhangHarvey F Lodish
Feb 7, 2006·Experimental Hematology·Hiroto ArakiRonald Hoffman
Feb 10, 2006·Proceedings of the National Academy of Sciences of the United States of America·Cheng Cheng ZhangHarvey F Lodish
Jun 2, 2006·Gene Therapy·S Cellot, G Sauvageau
Jun 6, 2006·Bone Marrow Transplantation·H SchoemansJ Wagner
Aug 1, 2006·The American Journal of Pathology·David BryderIrving L Weissman
Aug 11, 2006·Current Opinion in Biotechnology·Daniel C Kirouac, Peter W Zandstra

❮ Previous
Next ❯

Citations

Nov 11, 2011·Journal of Materials Science. Materials in Medicine·Mónica Ventura FerreiraSabine Neuss
Mar 23, 2012·International Journal of Hematology·Omar S Aljitawi
Jun 13, 2012·International Journal of Hematology·Liang HuangJianfeng Zhou
Mar 20, 2012·Cellular & Molecular Immunology·Adam C DrakeJianzhu Chen
Dec 8, 2009·Proceedings of the National Academy of Sciences of the United States of America·Qingfeng ChenJianzhu Chen
Jun 21, 2012·Tissue Engineering. Part C, Methods·Mónica Sofia Ventura FerreiraSabine Neuss
Jun 10, 2008·Current Opinion in Hematology·Cheng C Zhang, Harvey F Lodish
Jun 10, 2008·Current Opinion in Hematology·William TseMary J Laughlin
Oct 24, 2009·Current Opinion in Lipidology·Takashi Miida, Satoshi Hirayama
Dec 17, 2008·The Journal of Clinical Investigation·Stefano RomeoJonathan C Cohen
Nov 7, 2013·Journal of Hematology & Oncology·Xiaoli ChenCheng Cheng Zhang
Oct 8, 2011·Cell & Bioscience·Junke ZhengCheng Cheng Zhang
Mar 9, 2012·Vascular Health and Risk Management·Jane Hoover-Plow, Yanqing Gong
Oct 14, 2011·Viruses·Tobias MaetzigAxel Schambach
Dec 1, 2012·Stem Cells Translational Medicine·Gary Van Zant, Ying Liang
Jan 4, 2013·Stem Cells Translational Medicine·Eric E Bouhassira
Oct 1, 2013·Nanomedicine·K Vijaya KrishnaAlberto Bianco
May 19, 2012·Regenerative Medicine·Thomas Clapes, Catherine Robin
Mar 29, 2014·Experimental Hematology·Eun-ju LeeDavid Haylock
Jan 10, 2013·Annual Review of Immunology·Paul S FrenetteChristoph Scheiermann
Dec 23, 2011·Stem Cells International·Ekati DrakopoulouNicholas P Anagnou
Apr 14, 2010·Proceedings of the National Academy of Sciences of the United States of America·Song Chou, Harvey F Lodish
Feb 7, 2012·Cell Stem Cell·Sergei DoulatovJohn E Dick
Feb 7, 2012·Cell Stem Cell·Hans-Peter KiemJoseph M McCune
Apr 24, 2012·Expert Opinion on Biological Therapy·Taito NishinoAtsushi Iwama

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.